2026年A股开市了！首个交易日，三大指数早盘集体上涨，上证指数盘中重回4000点。盘面热点快速轮 动，脑机接口板块掀起涨停潮，倍益康"30cm"涨停，三博脑科等超20只个股涨停。保险板块表现活 跃，中国太保、新华保险盘中双双创历史新高。商业航天板块延续强势，金风科技等近20只个股封板。 此外，创新药、有色金属、游戏等板块盘中均表现积极。 您觉得哪个板块能成为2026年首周A股最热赛道？ 人脑工程板块掀涨停潮 创新药概念飙升 截至今日午间休市，沪指涨1.07%，深证成指涨1.87%，创业板指涨2.15%，沪深北三市半日成交16489 亿元，较上个交易日同期放量3240亿元。全市场超4000只个股上涨。人脑工程板块掀涨停潮，博拓生 物、熵基科技、三博脑科等10余只个股"20cm"涨停。 消息面上，埃隆·马斯克2025年12月31日在社交媒体上表示，其脑机接口公司"神经连接"（Neuralink） 将于2026年开始对脑机接口设备进行"大规模生产"，并转向"更加精简和几乎完全自动化的外科手术流 程"。（详见马斯克发声！301293，开盘"20cm"涨停） 开源证券最新研报表示，上述行业事件印证了脑机接口技术预计将 ...

Market Overview - The Hang Seng Index closed down 0.08% at 26,316.55 points, while the Hang Seng Tech Index fell 0.18% to 5,726.11 points. The National Enterprises Index decreased by 0.19% to 9,151.59 points, and the Red Chip Index rose by 0.38% to 4,099.43 points [1] Technology Sector - Alibaba-W increased by 2.28%, Tencent Holdings rose by 0.08%, while JD Group-SW fell by 1.13%, Xiaomi Group-W dropped by 2.53%, NetEase-S decreased by 2.71%, Meituan-W fell by 0.19%, Kuaishou-W surged by 9.66%, and Bilibili-W rose by 5.56% [1] Biopharmaceutical Sector - The biopharmaceutical sector saw significant gains, with Fuhong Hanlin rising by 7%. The National Medical Products Administration announced that by 2025, 76 innovative drugs will be approved for market, significantly exceeding the 48 approved in 2024, marking a historical high. Additionally, the total amount of authorized transactions for innovative drugs will exceed $130 billion, with over 150 transactions, also a historical high [1] Real Estate Sector - Domestic real estate stocks strengthened, with Shimao Group rising over 9%. An article in "Qiushi" magazine emphasized the critical role of real estate in national economic development, advocating for proactive measures to stabilize market expectations and reduce adjustment times. It highlighted the need for consistent policy strength that aligns with market expectations, avoiding piecemeal approaches that could lead to market-policy conflicts [1] Brain-Computer Interface Sector - The brain-computer interface concept surged, with Nanjing Panda Electronics rising over 44%. Elon Musk announced that his company Neuralink plans to begin large-scale production of brain-computer interface devices in 2026, with a streamlined and automated surgical process. A key breakthrough involves electrodes passing through the dura mater without removal, potentially reducing the invasiveness of traditional devices and optimizing efficiency and costs through automation [2] Oil Sector - Oil stocks weakened, with PetroChina falling over 4%. The U.S. launched military actions against Venezuela, capturing President Maduro. Trump stated that U.S. oil companies would invest billions to repair Venezuela's damaged oil infrastructure, aiding in capacity recovery and revenue generation, while maintaining a complete oil embargo against Venezuela [2]

2026年A股首个交易日，市场一片热闹景象。 一方面，上证指数再度站上4000点，日线迎来罕见的12连阳。另一方面，权重股搭台，个股普涨，热点全面开花。 权重股方面，保险板块大涨；此外，贵州茅台（600519）、宁德时代（300750）、中芯国际等龙头股均上涨。板块方面，脑机接口、医药、半导体、消费 电子等板块大涨。 截至上午收盘，上证指数上涨1.07%，报4011.45点；深证成指上涨1.87%，创业板指上涨2.15%。 | 新华保险 融 601336 | 74.95 | 7.53% | 1563 Z | | --- | --- | --- | --- | | 中国太保 | 44.49 | 6.16% | 3045亿 | | 融 601601 | | | | | 行业龙头3 | | | | | 中国平安 ■ 601318 | 72.20 | 5.56% | 7697亿 | | 行业龙头2 | | | | | 中国人寿 融 601628 | 47.85 | 5.16% | 9964 Z | | 行业龙头1 | | | | | 中国人保 融 601319 | 9.38 | 4.80% | 3330亿 | 202 ...

Group 1 - A-shares opened higher today, with significant gains in innovative drug and brain-computer interface stocks, including Zhaoyan New Drug and BeiGene, which rose over 10% [1] - The innovative drug ETF Tianhong (517380) tracking the Hang Seng-Hushen-Hong Kong Innovative Drug Selected 50 Index surged over 4.8%, outperforming the Hong Kong Stock Connect Innovative Drug Index [1] - The biopharmaceutical ETF (159859) tracking the Guozhen Biopharmaceutical Index increased by over 3%, with a total scale exceeding 3.3 billion yuan and a net inflow of over 600 million yuan since September last year [1] Group 2 - The National Medical Products Administration has organized the formulation of the "Priority Approval High-end Medical Device Catalog (2025 Edition)," including medical electronic accelerators and implantable brain-computer interface medical devices [1] - Elon Musk announced that his brain-computer interface company, Neuralink, will begin large-scale production of brain-computer interface devices in 2026, transitioning to a more streamlined and nearly fully automated surgical process [1] - Analysts indicate that including implantable brain-computer interface medical devices in the priority approval category highlights policy support for related technological developments, with a broad potential market space and accelerated commercialization processes expected [1] Group 3 - McKinsey estimates that the global market size for brain-computer interface medical applications could reach $40 billion by 2030 and $145 billion by 2040, indicating significant application potential in the medical field [2] - Investors interested in the innovative drug sector can consider the innovative drug ETF Tianhong (517380) for easy access, while off-market investors may focus on linked funds [2] - The emphasis is on CXO and innovative drug mainline trends, with a recommendation to focus on the biopharmaceutical ETF (159859) that targets 30 industry leaders for higher sharpness and elasticity [2]

2．保险 新华保险涨超7%，中国太保涨超6%，续创历史新高。 1月5日消息，市场早盘高开高走，时隔34个交易日，上证指数盘中重回4000点。板块方面，脑机接口概 念盘中持续扩大涨幅，乐普医疗、海格通信、三七互娱（维权）等超20股涨停；半导体产业链持续走 强，东微半导、兆易创新等多股涨停；创新药概念表现活跃，百济神州涨超10%；保险板块强势领涨， 新华保险涨超7%，中国太保涨超6%，双双创历史新高；下跌方面，海南自贸概念集体大跌，海南发展 跌停；银行板块大面积飘绿，浦发银行领跌。总体来看，个股呈普涨态势，上涨个股超4000只。 截至收盘，沪指报4011.45点，涨1.07%；深证成指报13777.32点，涨1.87%；创指报3272.07点，涨 2.15%。 盘面上，脑机接口、高压氧舱、保险板块涨幅居前，海南自贸区、海南、机场航运板块跌幅居前。 热点板块： 1．脑机接口 乐普医疗、海格通信、三七互娱等超20股涨停。 消息面上，马斯克近日在社交媒体上表示，其脑机接口公司Neuralink将于2026年开始对脑机接口设备进 行"大规模生产"。 4、【高盛预计中国央行今年一季度有一次"双降"】据高盛最新宏观展望报告， ...

Market Overview - The Shanghai Composite Index returned to 4000 points for the first time in 34 trading days, closing at 4011.45 points, up 1.07% [2] - The Shenzhen Component Index rose 1.87% to 13777.32 points, while the ChiNext Index increased by 2.15% to 3272.07 points [2] Key Sectors - The brain-computer interface sector saw significant gains, with over 20 stocks hitting the daily limit, including companies like Lepu Medical and 37 Interactive Entertainment [4] - The semiconductor industry continued to strengthen, with multiple stocks, including Dongwei Semiconductor, also reaching the daily limit [2] - The innovative drug sector was active, with BeiGene rising over 10% [2] Notable Performances - The insurance sector performed well, with New China Life Insurance increasing over 7% and China Pacific Insurance rising over 6%, both reaching historical highs [5] - The insurance industry reported a total premium income of 57,629 billion yuan for the first 11 months of 2025, a year-on-year increase of 7.6% [5] Economic Indicators - Beijing's artificial intelligence core industry is projected to reach a scale of 450 billion yuan by 2025, with over 2,500 companies expected to be concentrated in the area [6] - The China Logistics and Purchasing Federation reported a rise in the commodity price index to 117.9 points in December 2025, marking a 3.2% month-on-month increase and the highest level since June 2024 [7] Institutional Insights - Huaxi Securities anticipates a bullish market in 2026, driven by favorable macro policies and increased liquidity, with a focus on sectors like semiconductors and AI [9] - CITIC Construction Investment expects a strong start to the A-share market in 2026, with a favorable liquidity environment and multiple positive factors driving growth [9]

Core Viewpoint - The Hong Kong Stock Connect innovative drug ETF managed by E Fund (159316) has shown a strong rebound, rising over 4.5% in early trading, indicating positive market sentiment towards innovative drug development in China [1] Group 1: Innovative Drug Development - Innovent Biologics' anti-CTLA-4 monoclonal antibody "Daboshu" has been approved as the first domestic drug of its kind, filling a gap in the market [1] - The TROP2 ADC "Dercumab" jointly developed by AstraZeneca and Daiichi Sankyo has been approved for breast cancer indications in China, strengthening the ADC sector [1] Group 2: Business Development (BD) Growth - By December 31, 2025, the total transaction amount for China's innovative drug BD overseas licensing is expected to reach $135.655 billion, with upfront payments of $7 billion and a total of 157 transactions, marking historical highs across various metrics [1] - Recent BD transactions include: - Tongyi Medicine's peptide-conjugated drug CBP-1018 for prostate cancer licensed to MultiValent Biotherapies for $2 billion [1] - Ascletis Pharma's ADC drug SIM0613 licensed to Ipsen for $1.06 billion [1] - GRAIL's pan-KRAS inhibitor entering a Co-Co collaboration with AstraZeneca for over $2 billion, setting a record for clinical-stage small molecule collaborations [1] Group 3: Key Products - E Fund's Hong Kong Stock Connect innovative drug ETF (159316, linked A/C: 024328/024329) [1] - E Fund's Hong Kong Stock Connect pharmaceutical ETF (513200, linked A/C: 018557/018558) [1] - E Fund's Hang Seng Biotechnology ETF (159105) [1]

Core Viewpoint - The three major indices in the Chinese stock market opened higher and showed strong performance, with the Shanghai Composite Index surpassing 4000 points for the first time in 34 trading days, indicating a positive market sentiment and investor confidence [1] Market Performance - The Shanghai Composite Index rose by 1.07% at midday, while the Shenzhen Component Index increased by 1.87%, and the ChiNext Index gained 2.15% [1] - The market saw a surge in various sectors, particularly in brain engineering, insurance, semiconductor, innovative pharmaceuticals, and commercial aerospace [1] Sector Highlights - The brain engineering concept experienced a wave of stocks hitting the daily limit, with over 20 stocks including Sanbo Brain Science, Xiangyu Medical, Meihao Medical, and Aipeng Medical reaching the limit [1] - The insurance sector showed strong performance, with New China Life Insurance and China Pacific Insurance both reaching historical highs [1] - The storage chip concept also saw gains, with stocks like Zhaoyi Innovation and Yunhan Chip City hitting the daily limit [1] - The innovative pharmaceutical sector rose, with stocks such as Zhaoyan New Drug, Fuyuan Pharmaceutical, and Lepu Medical also reaching the limit [1] - The commercial aerospace sector remained active, with stocks like Reco Defense, Goldwind Technology, and Fenghuo Communication hitting the daily limit [1] Sector Performance - The leading sectors in terms of gains included insurance, healthcare, semiconductors, and the internet [1] - Conversely, sectors that experienced declines included hotel and catering, tourism, public transportation, and Hainan Free Trade [1]

Group 1 - The core viewpoint of the news is that the A-share and Hong Kong markets are experiencing a collective rise, with the Shanghai Composite Index surpassing 4000 points, indicating positive market sentiment [1] - The Hong Kong Stock Connect innovative drug index increased by 3.85%, with notable individual stock performances such as Zhaoyan New Drug rising over 11% and Tigermed and Kelun-Bio rising over 6% [1] - According to a report by Changjiang Securities, Zhaoyan New Drug is expected to see a 60% year-on-year growth in offshore outsourcing orders in 2024, driven by domestic safety evaluation demand recovery and resource scarcity [1] Group 2 - The China National Medical Products Administration reported that 76 innovative drugs have been approved for market in China by 2025, setting a historical record [1] - The total amount of authorized transactions for innovative drugs in China has exceeded $130 billion, with over 150 transactions, also a historical high [1] - Currently, China's pipeline of new drugs accounts for approximately 30% of the global total, ranking second worldwide [1] Group 3 - The Hong Kong Stock Connect innovative drug ETF managed by Harvest (520970) has a management and custody fee of 0.60% per year, making it suitable for both retail investors as a long-term investment tool and for professional investors seeking flexible trading options [2]

Core Viewpoint - Fujilay's stock price has shown a slight increase of 2.00% since the beginning of the year, with a current market capitalization of 3.039 billion yuan, indicating a stable performance in the pharmaceutical sector [1]. Group 1: Stock Performance - As of January 5, Fujilay's stock price reached 33.15 yuan per share, with a trading volume of 14.8913 million yuan and a turnover rate of 0.51% [1]. - The stock has experienced a 0.45% decline over the past five trading days, a 2.16% increase over the last 20 days, and a 1.37% decline over the past 60 days [1]. Group 2: Company Overview - Fujilay Pharmaceutical Co., Ltd. was established on November 27, 2000, and went public on March 29, 2022. The company is located in Changshu, Jiangsu Province [1]. - The main business activities include the research, production, and sales of active pharmaceutical ingredients (APIs) and health product raw materials [1]. - The revenue composition is as follows: 66.02% from lipoic acid products, 14.86% from carnosine products, 11.88% from etoricoxib, 5.95% from phosphatidylcholine products, and 1.29% from other supplements [1]. Group 3: Financial Performance - For the period from January to September 2025, Fujilay achieved an operating income of 323 million yuan, representing a year-on-year growth of 3.23%. The net profit attributable to the parent company was 73.3966 million yuan, showing a significant increase of 430.16% [1]. - Since its A-share listing, Fujilay has distributed a total of 153 million yuan in dividends, with 116 million yuan distributed over the past three years [2]. Group 4: Shareholder Information - As of December 19, 2025, the number of Fujilay's shareholders was 9,810, a slight decrease of 0.01% from the previous period, with an average of 9,079 circulating shares per person, which increased by 0.01% [1]. - As of September 30, 2025, the ninth largest circulating shareholder is Galaxy Kangle Stock A, holding 178,100 shares as a new shareholder [2].